切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2011, Vol. 05 ›› Issue (05) : 377 -382. doi: 10.3877/cma.j.issn.1674-0793.2011.05.003

所属专题: 经典病例 文献

论著

超声联合CT引导下经皮冷冻治疗胰腺癌85例
牛立志1, 何丽华1, 胡以则1, 吴炳辉1, 左建生1, 徐克成1,()   
  1. 1. 510305,广州复大肿瘤医院
  • 收稿日期:2011-05-25 出版日期:2011-10-01
  • 通信作者: 徐克成
  • 基金资助:
    广东省医学科研基金(WSTJJ20090401440106196602154756)

Percutaneous cryoablation for pancreatic cancer with ultrasonography and computed tomography guidance

Li-zhi NIU1, Li-hua HE1, Yi-ze HU1, Bing-hui WU1, Jian-sheng ZUO1, Ke-cheng XU1,()   

  1. 1. Department of oncology of the GIBH Affiliated Fuda Hospital, Chinese Academy of Sciences, 510305 Guangzhou, China
  • Received:2011-05-25 Published:2011-10-01
  • Corresponding author: Ke-cheng XU
  • About author:
    Corresponding author: XU Keneng, Email:
引用本文:

牛立志, 何丽华, 胡以则, 吴炳辉, 左建生, 徐克成. 超声联合CT引导下经皮冷冻治疗胰腺癌85例[J]. 中华普通外科学文献(电子版), 2011, 05(05): 377-382.

Li-zhi NIU, Li-hua HE, Yi-ze HU, Bing-hui WU, Jian-sheng ZUO, Ke-cheng XU. Percutaneous cryoablation for pancreatic cancer with ultrasonography and computed tomography guidance[J]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(05): 377-382.

目的

评估超声和CT引导经皮冷冻治疗胰腺癌的安全性及可行性。

方法

回顾性分析2008年11月至2010年5月在我院接受超声联合CT引导下经皮冷冻治疗的胰腺癌患者85例的临床资料,其中不可切除胰腺癌67例,拒绝手术治疗的可切除性胰腺癌患者18例,共计86个瘤灶接受121次经皮冷冻治疗。依据肿瘤的大小、形状及位置,分别选用1~8根探针。胰头癌采用经腹穿刺,胰体尾癌经腹或经背穿刺的方法。采用两个冷冻-复温循环,冷冻温度为(-160 ± 10)℃,复温温度(25 ± 5)℃,均持续5~10 min。于冷冻前后检查CT,评估状态(karnofsky performance status,KPS)评分,观察冷冻治疗后并发症及术后住院时间。

结果

全组121例次经皮冷冻治疗均顺利完成,无一例死亡。出院时KPS较治疗前提高(P < 0.01)。冷冻后1~3个月肿瘤平均直径明显缩小[(4.7 ± 0.3) vs. (4.1 ± 0.4),P < 0.01],所有瘤灶冷冻区活性消失。平均住院时间为(8.0 ± 0.6)d。

结论

超声联合CT引导经皮冷冻治疗胰腺癌安全可行,具有微创、准确、适形等特点,为临床胰腺癌治疗提供了新的技术手段。

Objective

To establish the standard technique of percutaneous cryoablaton for pancreatic cancer, assess the safety and feasibility of percutaneous cryoablation with ultrasonography(US) and computed tomography(CT) guidance in the treatment of pancreatic cancer.

Methods

review of 85 cases of pancreatic cancer who underwent cryoablations conducted from November 2008 to May 2010 was observed. Cryocare surgical system and cryoprobes in 1.7~2 cm were adopted. One to eight cryoprobes were supplied for each cryoablation. Transabdominal or transdorsal approach was performed for body and tail of pancreatic cancer, while transabdominal approach for head of pancreatic cancer. Two cycles of fast freezing with argon at (-160 ± 10)℃ for 5~10 min and thawing with helium at (15 ± 5)℃ for 5~10 min were performed for each ablation. CT, karnofsky performance status(KPS), cryoablation-related complications and hospital length of stay were analyzed.

Results

One hundred and twenty-one percutaneous cryoablaitons were performed successfully without deaths. Complications were relative infrequent, all of which were controlled well with conventional treatment. All cryolesions presented inactive status after cryoablation, and the average diameter of tumors decreased [(4.7 ± 0.3) vs. (4.1 ± 0.4), P < 0.01]. KPS increased [(80.0 ± 0.6) vs. (90.0 ± 0.4), P < 0.01]. Hospital length of stay was significantly shorter than of intraoperative cryoablations (P < 0.05).

Conclusions

Percutaneous cryoablation with US and CT guidance is a safe and feasible technique for pancreatic cancer with relatively rare and mild complications and irrefutably ablative effect, which provides an optimistic alternative therapy for pancreatic cancer.

表1 85例胰腺癌患者临床资料(例,%)
图1 超声联合CT引导经腹穿刺冷冻治疗胰头癌
图2 超声联合CT引导经背穿刺冷冻治疗胰体尾癌(囊腺癌,4.8 cm × 6.1 cm,Ⅳ期)(a)
图3 超声联合CT引导经皮冷冻治疗胰体癌前后CT影像对比
表2 85例胰腺癌患者经皮冷冻治并发症
1
Evans DB,Abbruzzese JL,Willet CG. Cancer of the Pancreas.In:DeVita VT,Hellman S,Rosemberg SA,eds. Cancer:principles and practice of oncology. 6th ed. Philadelphia:Lippincott Williams and Wilkins,2001:1126-1161.
2
Weber SM,Lee FT. Cryoablation:history,mechanism of action,and guidance modalities. New York:Springer-Verlag,2005,250-265.
3
Silverman SG,Tuncali K,Morrison PR. MR imaging-guided percutaneous tumor ablation. Acad Radiol,2005,12(9):1100-1109.
4
Babaian RJ,Donnelly B,Bahn D,et al. Best practice statement on Cryosurgery for the treatment of localized prostate cancer. J Urol,2008,180(5):1993-2004.
5
Wang H,Littrup PJ,Duan Y,et al. Thoracic masses treated with percutaneous cryotherapy:initial experience with more than 200 procedures. Radiology,2005,235(1):289-298.
6
Elhawary H,Oguro S,Tuncali K,et al. Multimodality non-rigid image registration for planning,targeting and monitoring during CT-guided percutaneous liver tumor cryoablation. Acad Radiol,2010,17(11):1334-1344.
7
Atwell TD,Callstrom MR,Farrell MA,et al. Percutaneous renal cryoablation:local control at mean 26 months of followup. J Urol,2010,184(4):1291-1295.
8
David C,Niu LZ,Mu F,et al. The experimental study for efficacy and safety of pancreatic cryosurgery. Cryobiology,2010,60(3):281-286.
9
Petrone MC,Arcidiacono PG,Carrara S,et al. US-guided application of a new hybrid probe in human pancreatic adenocarcinoma:an ex vivo study. Gastrointest Endosc,2010,71(7):1294-1297.
10
Korpan NN,Hochwarter G,Sellner F. Cryoscience and cryomedicine:new mechanisms of biological tissue injury following low temperature exposure. Experimental study. Klin Khir,2009,(7-8):80-85.
11
李波,李敬东,陈晓理,等. 无法切除的胰腺癌的冷冻手术治疗(附44例报告). 中华肝胆外科杂志,2004,10(8):523-525.
12
Kovach SJ,Hendrickson I,Cappadona CR,et al. Cryoablation of unresectable pancreatic cancer. Surgery,2002,131:463-464.
13
Chen XL,Ma Y,Wan Y,et al. Experimental study of the safety of pancreas cryosurgery:the comparison of 2 different techniques of cryosurgery. Pancreas,2010,39(1):92-96.
14
Xu KC,Niu LZ,Hu YZ,et al. Apilot study on combination of cryosurgery and(125)iodine seed implantation for treatment of locally advanced pancreatic cancer. World J Gastroenterol,2008,14(10):1603-1611.
[1] 贺强, 郎韧. 动脉入路联合血管切除、异体血管置换的胰十二指肠切除术[J]. 中华普通外科学文献(电子版), 2020, 14(04): 0-0.
[2] 尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[3] 王勤运, 许大彬, 张恩犁, 钱海, 赵之明. 完全脏器转位机器人胰十二指肠切除术一例[J]. 中华腔镜外科杂志(电子版), 2023, 16(01): 52-55.
[4] 贾勇, 刘红阳, 张宾儒, 李林峰, 王浩年, 陈华, 孙备. 腹腔镜对比开腹远端胰腺切除术治疗胰腺导管腺癌的Meta分析[J]. 中华腔镜外科杂志(电子版), 2021, 14(01): 37-43.
[5] 王琛, 樊勇, 夏博伟. 微创时代下胰腺癌诊疗进展[J]. 中华腔镜外科杂志(电子版), 2019, 12(05): 311-316.
[6] 朱春宇, 刘荣. 胰十二指肠切除术中静脉切除重建的研究现状[J]. 中华腔镜外科杂志(电子版), 2019, 12(05): 301-306.
[7] 李新雄, 张再重, 赵虎, 肖春红, 王烈. 作为胰腺癌生物标志物的外泌体内容物研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(01): 53-57.
[8] 韩连强, 谭杨, 杨奇, 闫明先. 胰腺癌治疗进展[J]. 中华消化病与影像杂志(电子版), 2019, 09(02): 49-54.
[9] 曹文玺, 陈箫, 竺来法, 周永平. 尼妥珠单抗联合白蛋白结合型紫杉醇治疗胰腺癌的有效性及安全性分析[J]. 中华临床医师杂志(电子版), 2023, 17(04): 409-413.
[10] 任刚, 沈光凯, 王颖杰. 胰腺癌消融放疗的研究进展[J]. 中华临床医师杂志(电子版), 2022, 16(12): 1276-1279.
[11] 任刚, 沈光凯, 宋佳钊, 李晶, 王勇, 王颖杰. 高剂量少分次放疗对胰腺癌患者免疫功能、营养及体力状态的影响[J]. 中华临床医师杂志(电子版), 2022, 16(09): 876-880.
[12] 张鑫, 谢凤姣, 刘云飞, 肖强胜. 预防性输注新鲜冰冻血浆对胰十二指肠切除术患者的近期疗效观察[J]. 中华临床医师杂志(电子版), 2020, 14(02): 99-104.
[13] 辛玉晶, 陈毅, 王亚楠, 杨伊, 周翔. 超声引导125I粒子腹腔神经节植入术治疗进展期胰腺癌疼痛的疗效分析[J]. 中华介入放射学电子杂志, 2020, 08(01): 38-43.
[14] 陈升鑫, 翟亚奇, 卜保国, 陈德鑫, 吴浪, 方开萱, 刘文静, 李明阳, 令狐恩强. 自身免疫性胰腺炎临床特征分析[J]. 中华胃肠内镜电子杂志, 2023, 10(01): 46-51.
[15] 杨珍, 虎金朋, 牛敏, 周燕, 张玲, 张雪, 白飞虎. 他汀类药物在消化系统癌症中的使用研究进展[J]. 中华胃肠内镜电子杂志, 2019, 06(03): 125-129.
阅读次数
全文


摘要